OP-1250 works well in combination with cyclin-dependent kinase 4 and 6 inhibitors in preclinical studies, leading to significant tumor shrinkage in intracranial breast cancer models and extending the lifespan of the test subjects. Here, CDK4 is linked to breast cancer.